Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2023-02-21 00:00:00 ET · period of report 2023-02-16 · accession 0001104659-23-023834 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-21 | 2023-02-16 | SUPN | Martin Tami Tillotson | SVP, Regulatory Affairs | M - OptEx | $0.00 | +1,500 | 88.7K | +2% | $0 |
| D | 2023-02-21 | 2023-02-16 | SUPN | Martin Tami Tillotson | SVP, Regulatory Affairs | M - OptEx | $0.00 | -1,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-16 | M | A | 1,500 | $0.00 | 88,720 | D | — | — | (F1) Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on April 30, 2021. |
| 2 | Derivative | Performance Share Unit | 2023-02-16 | M | D | 1,500 | $0.00 | 0 | D | $0.00 · — to 2031-04-30 | 1,500 Common Stock | (F2) On April 30, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. |